Global Adalimumab Injection Supply, Demand and Key Producers, 2023-2029

Global Adalimumab Injection Supply, Demand and Key Producers, 2023-2029

The global Adalimumab Injection market size is expected to reach $ 2698.8 million by 2029, rising at a market growth of 5.4% CAGR during the forecast period (2023-2029).

This report studies the global Adalimumab Injection production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Adalimumab Injection, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Adalimumab Injection that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Adalimumab Injection total production and demand, 2018-2029, (K Units)

Global Adalimumab Injection total production value, 2018-2029, (USD Million)

Global Adalimumab Injection production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Adalimumab Injection consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Adalimumab Injection domestic production, consumption, key domestic manufacturers and share

Global Adalimumab Injection production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Adalimumab Injection production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Adalimumab Injection production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)

This reports profiles key players in the global Adalimumab Injection market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd. and Hisun Biopharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Adalimumab Injection market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Adalimumab Injection Market, By Region:

United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Adalimumab Injection Market, Segmentation by Type

40mg/0.8ml
20mg/0.4ml

Global Adalimumab Injection Market, Segmentation by Application

Hospitals
Clinics
Others

Companies Profiled:
AbbVie
Amgen
Sandoz
Fresenius Kabi
Biogen
Celltrion
Cadila Pharmaceuticals
Bio-Thera Solutions, Ltd.
Hisun Biopharmaceutical
Innovent Biologics
Mylan
Zydus Group
Boehringer Ingelheim
Jiangsu Chia Tai-Tianqing Pharmaceutical
Shanghai Henlius Biotech

Key Questions Answered

1. How big is the global Adalimumab Injection market?

2. What is the demand of the global Adalimumab Injection market?

3. What is the year over year growth of the global Adalimumab Injection market?

4. What is the production and production value of the global Adalimumab Injection market?

5. Who are the key producers in the global Adalimumab Injection market?

6. What are the growth factors driving the market demand?